Namba K, Nakajima R, Otani T, Azuma I
New Product Research Laboratories 1, Daiichi Pharmaceutical Co., Ltd, Tokyo, Japan.
Vaccine. 1996 Aug;14(12):1149-53. doi: 10.1016/0264-410x(96)00015-1.
Romurtide given orally enhanced the nonspecific resistance against microbial infections and hematopoiesis up to the levels achieved by subcutaneous (s.c.) injection of the compound in mice. Oral romurtide conferred protection and, in consequence, enhanced therapeutic efficacy of antibiotics against systemic infections in mice. The leukocytosis followed by the elevations of colony stimulating activity in serum and the colony forming unit of granulocyte-macrophage (c.f.u.-GM) in femoral bone marrow was observed as successive event in mice treated orally with romurtide. To obtain a comparable potency to s.c. injection of the compound at a dose of 0.1 mg per mouse, oral application required doses of 3 and 10 mg per mouse for stimulating the nonspecific resistance to infection and hematopoiesis, respectively.
口服罗穆肽可增强对微生物感染的非特异性抵抗力和造血功能，使其达到在小鼠皮下注射该化合物所达到的水平。口服罗穆肽具有保护作用，因此增强了抗生素对小鼠全身感染的治疗效果。在口服罗穆肽治疗的小鼠中，观察到白细胞增多，随后血清中集落刺激活性和股骨骨髓中粒细胞-巨噬细胞集落形成单位（c.f.u.-GM）升高，这些是相继发生的事件。为了获得与每只小鼠皮下注射0.1 mg该化合物相当的效力，口服给药分别需要每只小鼠3 mg和10 mg的剂量来刺激对感染的非特异性抵抗力和造血功能。
